{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T22:03:10Z","timestamp":1787522590194,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41401-019-0283-z","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T13:07:35Z","timestamp":1563973655000},"page":"129-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1\/3 and MRP2"],"prefix":"10.1038","volume":"41","author":[{"given":"Xiao-ying","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang-qiang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-ji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-ye","family":"Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-yu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"283_CR1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis."},{"key":"283_CR2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","volume":"41","author":"Rozman","year":"2002","unstructured":"Rozman. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002;41:421\u201330.","journal-title":"Clin Pharmacokinet."},{"key":"283_CR3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1124\/dmd.31.10.1240","volume":"31","author":"AS Kalgutkar","year":"2003","unstructured":"Kalgutkar AS, Nguyen HT, Vaz ADN, Doan A, Dalvie DK, McLeod DG, et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726. Drug Metab Dispos. 2003;31:1240\u201350.","journal-title":"Drug Metab Dispos"},{"key":"283_CR4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/mol.117.110593","volume":"93","author":"L Wang","year":"2018","unstructured":"Wang L, Ma LL, Lin Y, Liu X, Xiao L, Zhang Y, et al. Leflunomide increases hepatic exposure to methotrexate and its metabolite by differentially regulating multidrug resistance-associated protein Mrp2\/3\/4 transporters via peroxisome proliferator-activated receptor alpha activation. Mol Pharmacol. 2018;93:563\u201374.","journal-title":"Mol Pharmacol"},{"key":"283_CR5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bcp.2005.06.024","volume":"70","author":"H Ueo","year":"2005","unstructured":"Ueo H, Motohashi H, Katsura T, Inui K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005;70:1104\u201313.","journal-title":"Biochem Pharmacol"},{"key":"283_CR6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/00498250801927435","volume":"38","author":"C Srimaroeng","year":"2008","unstructured":"Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica 2008;38:889\u2013935.","journal-title":"Xenobiotica"},{"key":"283_CR7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12882-018-1121-0","volume":"19","author":"JS Chavez-Iniguez","year":"2018","unstructured":"Chavez-Iniguez JS, Medina-Gonzalez R, Aguilar-Parra L, Torres-Vazquez EJ, Maggiani-Aguilera P, Cervantes-Perez E, et al. Oral acyclovir induced hypokalemia and acute tubular necrosis a case report. BMC Nephrol. 2018;19:324.","journal-title":"BMC Nephrol."},{"key":"283_CR8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","volume":"29","author":"J Piret","year":"2016","unstructured":"Piret J, Boivin G. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis. 2016;29:654\u201362.","journal-title":"Curr Opin Infect Dis."},{"key":"283_CR9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.antiviral.2018.01.008","volume":"151","author":"M Mercier-Darty","year":"2018","unstructured":"Mercier-Darty M, Boutolleau D, Lepeule R, Rodriguez C, Burrel S. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations. Antivir Res. 2018;151:20\u20133.","journal-title":"Antivir Res."},{"key":"283_CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0002-9343(82)90094-8","volume":"73","author":"P de Miranda","year":"1982","unstructured":"de Miranda P, Good SS, Krasny HC, Connor JD, Laskin OL, Lietman PS. Metabolic fate of radioactive acyclovir in humans. Am J Med. 1982;73:215\u201320.","journal-title":"Am J Med."},{"key":"283_CR11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.21.5.804","volume":"21","author":"OL Laskin","year":"1982","unstructured":"Laskin OL, de Miranda P, King DH, Page DA, Longstreth JA, Rocco L, et al. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother. 1982;21:804\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"283_CR12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.46.2.458-463.2002","volume":"46","author":"F De Bony","year":"2002","unstructured":"De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002;46:458\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"283_CR13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1734-1140(13)71026-0","volume":"65","author":"J Ye","year":"2013","unstructured":"Ye J, Liu Q, Wang C, Meng Q, Sun H, Peng J, et al. Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3. Pharmacol Rep. 2013;65:505\u201312.","journal-title":"Pharmacol Rep."},{"key":"283_CR14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2012.06.004","volume":"47","author":"J Ye","year":"2012","unstructured":"Ye J, Liu Q, Wang C, Meng Q, Peng J, Sun H, et al. Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3. Eur J Pharm Sci. 2012;47:341\u20136.","journal-title":"Eur J Pharm Sci"},{"key":"283_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jop.2008.0084","volume":"25","author":"PK Karla","year":"2009","unstructured":"Karla PK, Quinn TL, Herndon BL, Thomas P, Pal D, Mitra A. Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. J Ocul Pharmacol Ther. 2009;25:121\u201332.","journal-title":"J Ocul Pharmacol Ther."},{"key":"283_CR16","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/toxins2082055","volume":"2","author":"Y Hagos","year":"2010","unstructured":"Hagos Y, Wolff NA. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins. 2010;2:2055\u201382.","journal-title":"Toxins"},{"key":"283_CR17","doi-asserted-by":"crossref","first-page":"e014032","DOI":"10.1136\/bmjopen-2016-014032","volume":"7","author":"TL Liao","year":"2017","unstructured":"Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7:e014032.","journal-title":"BMJ Open."},{"key":"283_CR18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.semarthrit.2018.03.011","volume":"48","author":"FM Kudaeva","year":"2019","unstructured":"Kudaeva FM, Speechley MR, Pope JE. A systematic review of viral exposures as a risk for rheumatoid arthritis. Semin Arthritis Rheum. 2019;48:587\u201396.","journal-title":"Semin Arthritis Rheum."},{"key":"283_CR19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57:1431\u20138.","journal-title":"Arthritis Rheum."},{"key":"283_CR20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/0886022X.2018.1487866","volume":"40","author":"EJ Lee","year":"2018","unstructured":"Lee EJ, Jang HN, Cho HS, Bae E, Lee TW, Chang SH, et al. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration. Ren Fail. 2018;40:687\u201392.","journal-title":"Ren Fail."},{"key":"283_CR21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jpeds.2015.01.023","volume":"166","author":"S Rao","year":"2015","unstructured":"Rao S, Abzug MJ, Carosone-Link P, Peterson T, Child J, Siparksy G, et al. Intravenous acyclovir and renal dysfunction in children: a matched case control study. J Pediatr. 2015;166:1462\u20138. e1-4","journal-title":"J Pediatr."},{"key":"283_CR22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0272-6386(12)80939-5","volume":"22","author":"BN Becker","year":"1993","unstructured":"Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis. 1993;22:611\u20135.","journal-title":"Am J Kidney Dis."},{"key":"283_CR23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00467-002-0867-5","volume":"17","author":"G Vomiero","year":"2002","unstructured":"Vomiero G, Carpenter B, Robb I, Filler G. Combination of ceftriaxone and acyclovir-an underestimated nephrotoxic potential? Pedia Nephrol. 2002;17:633\u20137.","journal-title":"Pedia Nephrol."},{"key":"283_CR24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1139\/Y10-023","volume":"88","author":"P Gunness","year":"2010","unstructured":"Gunness P, Aleksa K, Kosuge K, Ito S, Koren G. Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity. Can J Physiol Pharmacol. 2010;88:448\u201355.","journal-title":"Can J Physiol Pharmacol."},{"key":"283_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00856544","volume":"8","author":"T Ahmad","year":"1994","unstructured":"Ahmad T, Simmonds M, McIver AG, McGraw ME. Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis. Pedia Nephrol. 1994;8:489\u201391.","journal-title":"Pedia Nephrol."},{"key":"283_CR26","doi-asserted-by":"crossref","first-page":"e103185","DOI":"10.1371\/journal.pone.0103185","volume":"9","author":"H Lu","year":"2014","unstructured":"Lu H, Han YJ, Xu JD, Xing WM, Chen J. Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model. PLoS One. 2014;9:e103185.","journal-title":"PLoS One"},{"key":"283_CR27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/aps.2015.157","volume":"37","author":"LL Ma","year":"2016","unstructured":"Ma LL, Wu ZT, Wang L, Zhang XF, Wang J, Chen C, et al. Inhibition of hepatic cytochrome P450 enzymes and sodium\/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity. Acta Pharmacol Sin. 2016;37:415\u201324.","journal-title":"Acta Pharmacol Sin."},{"key":"283_CR28","doi-asserted-by":"crossref","first-page":"e0202706","DOI":"10.1371\/journal.pone.0202706","volume":"13","author":"M Ceckova","year":"2018","unstructured":"Ceckova M, Reznicek J, Deutsch B, Fromm MF, Staud F. Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate). PLoS One. 2018;13:e0202706.","journal-title":"PLoS One"},{"key":"283_CR29","doi-asserted-by":"crossref","first-page":"e00837","DOI":"10.1128\/AAC.00837-17","volume":"61","author":"J Reznicek","year":"2017","unstructured":"Reznicek J, Ceckova M, Ptackova Z, Martinec O, Tupova L, Cerveny L, et al. MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir and effect on intestinal absorption. Antimicrob Agents Chemother. 2017;61:e00837\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"283_CR30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.foodchem.2019.03.111","volume":"291","author":"Y Fang","year":"2019","unstructured":"Fang Y, Cao W, Liang F, Xia M, Pan S, Xu X. Structure affinity relationship and docking studies of flavonoids as substrates of multidrug-resistant associated protein 2 (MRP2) in MDCK\/MRP2 cells. Food Chem. 2019;291:101\u20139.","journal-title":"Food Chem"},{"key":"283_CR31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jep.2015.07.011","volume":"172","author":"L Ma","year":"2015","unstructured":"Ma L, Qin Y, Shen Z, Bi H, Hu H, Huang M, et al. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2. J Ethnopharmacol. 2015;172:430\u20135.","journal-title":"J Ethnopharmacol"},{"key":"283_CR32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1074\/jbc.M110.139949","volume":"286","author":"MA Nagle","year":"2011","unstructured":"Nagle MA, Truong DM, Dnyanmote AV, Ahn SY, Eraly SA, Wu W, et al. Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling. J Biol Chem. 2011;286:243\u201351.","journal-title":"J Biol Chem"},{"key":"283_CR33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","volume":"56","author":"A Ivanyuk","year":"2017","unstructured":"Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56:825\u201392.","journal-title":"Clin Pharmacokinet."},{"key":"283_CR34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1152\/physrev.00025.2013","volume":"95","author":"SK Nigam","year":"2015","unstructured":"Nigam SK, Bush KT, Martovetsky G, Ahn SY, Liu HC, Richard E, et al. The organic anion transporter (OAT) family: a systems biology perspective. Physiol Rev. 2015;95:83\u2013123.","journal-title":"Physiol Rev"},{"key":"283_CR35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejphar.2008.02.085","volume":"585","author":"AA El-Sheikh","year":"2008","unstructured":"El-Sheikh AA, Masereeuw R, Russel FG. Mechanisms of renal anionic drug transport. Eur J Pharmacol. 2008;585:245\u201355.","journal-title":"Eur J Pharmacol."},{"key":"283_CR36","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1021\/mp100418u","volume":"8","author":"X Xue","year":"2011","unstructured":"Xue X, Gong LK, Maeda K, Luan Y, Qi XM, Sugiyama Y, et al. Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol Pharmacol. 2011;8:2183\u201392.","journal-title":"Mol Pharmacol."},{"key":"283_CR37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002239705","volume":"43","author":"DL Wolf","year":"2003","unstructured":"Wolf DL, Rodr\u00edguez CA, Mucci M, Ingrosso A, Duncan BA, Nickens DJ. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol. 2003;43:43\u201351.","journal-title":"J Clin Pharmacol."},{"key":"283_CR38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.106.028233","volume":"71","author":"T Imaoka","year":"2007","unstructured":"Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71:619\u201327.","journal-title":"Mol Pharmacol."},{"key":"283_CR39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2133\/dmpk.24.37","volume":"24","author":"YS Hiroyuki Kusuhara","year":"2009","unstructured":"Hiroyuki Kusuhara YS. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet. 2009;24:37\u201352.","journal-title":"Drug Metab Pharmacokinet."},{"key":"283_CR40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2133\/dmpk.23.223","volume":"23","author":"K Maeda","year":"2008","unstructured":"Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet. 2008;23:223\u201335.","journal-title":"Drug Metab Pharmacokinet."},{"key":"283_CR41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","volume":"328","author":"T Watanabe","year":"2009","unstructured":"Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328:652\u201362.","journal-title":"J Pharmacol Exp Ther."},{"key":"283_CR42","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/ard.2007.086264","volume":"68","author":"E Kis","year":"2009","unstructured":"Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009;68:1201\u20137.","journal-title":"Ann Rheum Dis."},{"key":"283_CR43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01213011-200505000-00002","volume":"15","author":"JS Hulot","year":"2005","unstructured":"Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics. 2005;15:277\u201385.","journal-title":"Pharmacogenet Genomics."},{"issue":"12","key":"283_CR44","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1097\/TP.0000000000002689","volume":"103","author":"Jordan M. Chiasson","year":"2019","unstructured":"Chiasson JM, Fominaya CE, Gebregziabher M, Taber DJ. Long-term assessment of NSAID prescriptions and potential nephrotoxicity risk in adult kidney transplant recipients. Transplantation. 2019; \nhttps:\/\/doi.org\/10.1097\/TP.0000000000002689\n\n.","journal-title":"Transplantation"},{"key":"283_CR45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1060028018789174","volume":"53","author":"AB Pai","year":"2019","unstructured":"Pai AB, Divine H, Marciniak M, Morreale A, Saseen JJ, Say K, et al. Need for a judicious use of nonsteroidal anti-inflammatory drugs to avoid community-acquired acute kidney injury. Ann Pharmacother. 2019;53:95\u2013100.","journal-title":"Ann Pharmacother."},{"key":"283_CR46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1124\/jpet.115.229104","volume":"356","author":"A Kawase","year":"2016","unstructured":"Kawase A, Yamamoto T, Egashira S, Iwaki M. Stereoselective inhibition of methotrexate excretion by glucuronides of nonsteroidal anti-inflammatory drugs via multidrug resistance proteins 2 and 4. J Pharmacol Exp Ther. 2016;356:366\u201374.","journal-title":"J Pharmacol Exp Ther."},{"key":"283_CR47","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1124\/jpet.107.121491","volume":"322","author":"Y Nozaki","year":"2007","unstructured":"Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, et al. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther. 2007;322:1162\u201370.","journal-title":"J Pharmacol Exp Ther."},{"key":"283_CR48","first-page":"2072","volume":"22","author":"JM Kremer","year":"1995","unstructured":"Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol. 1995;22:2072\u20137.","journal-title":"J Rheumatol."},{"key":"283_CR49","first-page":"248","volume":"5","author":"DM Moss","year":"2014","unstructured":"Moss DM, Neary M, Owen A. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol. 2014;5:248.","journal-title":"Front Pharmacol."},{"key":"283_CR50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1248\/bpb.b17-00547","volume":"41","author":"Z Yue","year":"2018","unstructured":"Yue Z, Shi J, Li H, Li H. Association between concomitant use of acyclovir or valacyclovir with NSAIDs and an increased risk of acute kidney injury: data mining of FDA adverse event reporting system. Biol Pharm Bull. 2018;41:158\u201362.","journal-title":"Biol Pharm Bull"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0283-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:15Z","timestamp":1684616535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-019-0283-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1038\/s41401-019-0283-z","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}